Listen to this article 2 min The drugmaker has left its longtime headquarters in Rockland to join one of the fastest-growing ...

The building in Woodcliff Lake rose in value despite the trend away from suburban office space with work-from-home and a shift back to urban centers.

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic spontaneous urticaria.

Stop by Bell Tower at 520 Main Avenue Sept. 9 - 13 to meet members of the Bell team and register for prizes. Bell Bank is seen on Wednesday, Sept. 4, 2024, located on Main Avenue in downtown Fargo ...

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two ...

The Chennai campus, which was the operational base for Cognizant co-founders Lakshmi Narayanan and Chandrasekaran, is historically significant for the company. It was here that Cognizant remotely ...

Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up ...

Also Read: Sanofi’s Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant. Preliminary analysis of liver safety was consistent with ...

Legal & General Group Plc has signed a lease for a new City of London headquarters that’s a block away from its existing base. The UK asset manager has rented 190,000 square feet (17,652 square ...

London: Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in ...

The po­ten­tial of Sanofi’s close­ly-watched BTK in­hibitor in mul­ti­ple scle­ro­sis is com­ing in­to clear­er view amid plans to nar­row the fo­cus of the French com­pa­ny’ … ...

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease ...